Dr. Binod Dhakal is an esteemed hematologist-oncologist 🩸🎗️ and Associate Professor at the Medical College of Wisconsin 🏥. He holds an M.D. from Saint Francis Hospital and an MBBS from Manipal College of Medical Sciences, with an M.S. in Clinical & Translational Science. His research focuses on multiple myeloma, CAR-T cell therapy, and cancer immunotherapy 🧬. Dr. Dhakal has secured multimillion-dollar grants 💰, received prestigious awards 🏅, and serves as a reviewer for leading oncology journals 📖. His contributions to oncology research and education make him a top contender for the Best Researcher Award.
Dr Binod Dhakal, Medical College of Wisconsin, United States
Profile
GOOGLESCHOLAR
SCOPUS
Education🎓
Dr. Binod Dhakal has an impressive academic journey in medicine and oncology 🏥🔬. He earned his MBBS from Manipal College of Medical Sciences, Nepal 🇳🇵 (1999-2004) and later completed his M.D. at Saint Francis Hospital, Evanston, IL, USA 🇺🇸 (2007-2010). He specialized further as a Hematology/Oncology Fellow at the Medical College of Wisconsin (2013-2016) 🩸🎗️. To strengthen his research expertise, he obtained an M.S. in Clinical & Translational Science from the Clinical and Translational Institute of Southeast Wisconsin (2015-2016) 📊🧬. His extensive education underscores his commitment to advancing cancer research and patient care.
Awards and Honors 🏆
Dr. Binod Dhakal is a highly acclaimed hematologist-oncologist 🎗️, recognized for his excellence in medical research and education 📚. He has received numerous prestigious awards, including the American Society of Oncology Travel Trainee Award ✈️, Best Oral Abstract Award 🏅, and Outstanding Medical Student Teacher Award 🏫. His leadership was further acknowledged as Chief Fellow in Hematology/Oncology 🏥. Dr. Dhakal’s groundbreaking work in multiple myeloma and cancer immunotherapy 🧬 has earned him esteemed fellowships and research accolades. His dedication to advancing oncology and mentoring future physicians makes him a leading figure in the field.
Contributions 👨🏫
Dr. Binod Dhakal is a dedicated mentor and faculty leader, guiding numerous fellows and researchers in multiple myeloma studies 🩸🧬. Since 2016, he has mentored Guru Subramaniam in research and MS thesis development. His mentorship extends to esteemed fellows like Smith Giri (2018-Present), Madan Aryal (2018-2022), Lindsay Hammons (2021-2023), and Ramsha Ahmed (2022-Present) 📚🔍. His contributions continue with Bicky Thapa, Gulrayz Ahmed, Ravi Narra, Jennifer Obasi, Othman Akhtar, Fumou Sun, and Kritika Yadav, ensuring future advancements in hematology and oncology. His commitment to training the next generation of experts solidifies his impact in medical research.
Books Chapters 📖
Dr. Binod Dhakal has made significant contributions to medical literature through books, chapters, and editorial works 📚📝. His 2011 piece, Medical Student Perspectives: Journey Through Different Worlds, explores user-driven healthcare. He co-authored statistical analysis discussions in Current Concepts and Controversies in Hematopoietic Cell Transplantation (2014) 📊📖. His works on allogeneic stem cell transplantation and CAR-T therapy in multiple myeloma (2015-2020) in Bone Marrow Transplantation and Blood Reviews provide crucial insights into hematology and oncology 🩸🧬. His expertise in narrative medicine, stem cell therapy, and cancer research continues to shape the field.
Research Focus 🔬
Dr. Binod Dhakal’s research primarily focuses on multiple myeloma, hematopoietic cell transplantation (HCT), and CAR-T cell therapy 🧬🧑⚕️. His work explores stem cell mobilization with novel induction therapies, B-cell maturation antigen (BCMA)-directed immunotherapy, and cytokine release syndrome in HCT patients 💉🦠. He has investigated the role of beta-blockers like propranolol in reducing molecular risk markers and examined the ethical challenges in CAR-T cell therapy slot allocation ⚖️🔍. His research provides groundbreaking insights into improving transplant success rates and reducing treatment-related complications, shaping the future of oncology and hematology. 🚀📚
Publications 📚
“Cilta-cel or standard care in lenalidomide-refractory multiple myeloma” 🧬💊
🖊 Authors: J. San-Miguel, B. Dhakal, K. Yong, A. Spencer, S. Anguille, M.V. Mateos, et al.
📖 Journal: New England Journal of Medicine 🏥
📅 Year: 2023
📊 Citations: 400
“Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma (OPTIMISMM): a randomised, open-label study” 💉🔬
🖊 Authors: P.G. Richardson, A. Oriol, M. Beksac, A.M. Liberati, M. Galli, F. Schjesvold, et al.
📖 Journal: The Lancet Oncology 🏥
📅 Year: 2019
📊 Citations: 400
“Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma” 🦠🩸
🖊 Authors: L.J. Costa, S. Chhabra, E. Medvedova, B.R. Dholaria, T.M. Schmidt, K.N. Godby, et al.
📖 Journal: Journal of Clinical Oncology 🏥
📅 Year: 2022
📊 Citations: 220
“Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis” 🏥📊
🖊 Authors: B. Dhakal, A. Szabo, S. Chhabra, M. Hamadani, A. D’Souza, S.Z. Usmani, et al.
📖 Journal: JAMA Oncology 🩺
📅 Year: 2018
📊 Citations: 187